世界のアルブミン市場2021年-2028年:種類別(ヒト血清、ウシ血清、組換え体)、用途別(治療、製剤、その他)、地域別

【英語タイトル】Albumin Market by Type (Human Serum, Bovine Serum, and Recombinant), Application (Therapeutics, Drugs Formulation, and Others), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2028

Research Diveが出版した調査資料(RDV22AU024)・商品コード:RDV22AU024
・発行会社(調査会社):Research Dive
・発行日:2022年4月
・ページ数:175
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single UserUSD5,700 ⇒換算¥843,600見積依頼/購入/質問フォーム
5 UserUSD8,700 ⇒換算¥1,287,600見積依頼/購入/質問フォーム
Enterprise UserUSD10,700 ⇒換算¥1,583,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Research Dive社の当調査資料では、世界のアルブミン市場について多面的に分析し、調査手法、エグゼクティブサマリー、市場概要、種類別(ヒト血清、ウシ血清、組換え体)分析、用途別(治療、製剤、その他)分析、地域別分析、企業情報などの内容をまとめております。なお、当書に掲載されている企業情報には、Baxter International Inc.、China Biologic Products、Inc、CSL Limited、Grifols、S.A.、Merck KGaA、Novozymes、Octapharma AG、Takeda Pharmaceuticals Inc、Thermo Fisher Scientific、Ventria Bioscience.などが含まれています。
・調査手法
・エグゼクティブサマリー
・市場概要
・世界のアルブミン市場規模:種類別(ヒト血清、ウシ血清、組換え体)
・世界のアルブミン市場規模:用途別(治療、製剤、その他)
・世界のアルブミン市場規模:地域別
・企業情報

According to Research Dive analysis, the albumin market is estimated to be valued at $8,129.1 million by 2028, surging from $4,157.2 million in 2020, at a noteworthy CAGR of 10.1%

Impact Analysis of COVID-19 on the Albumin Market
The COVID-19 pandemic had a positive impact on the albumin market. Rapidly increasing infection cases across the world have paced up the demand for the development of vaccine to prevent any severe complications against the COVID-19 virus. For this, the researchers & scientists along with biotechnological & biopharmaceutical industries have increased their research & development activities to develop high potential drug or a vaccine with the help of albumin. This factor is likely to boost the market growth in the coming years.

Albumin Market Analysis
Rapidly increasing research activities on eukaryotic cells in academic & research centers, biopharmaceutical industries, and other segments and growing use of albumin rich cell growth medium for such research activities are likely to flourish albumin market share growth in the coming years. Also, albumin provides most nutrients and minerals required by the cells to grow properly in an artificial environment. This factor is expected to drive the market of albumin in the coming years.
However, many side effects associated with albumin treatment like fever, itching, and rashes are likely to restrain the market growth. Also, albumin therapeutics are very costly and cannot be afforded by most people in developing countries which is further likely to restrain the market growth even further.
Growing research activities on various chronic diseases such as cancer are anticipated to drive the market of albumin because albumin provides all necessary growth factors used for expression of cancer cells in research laboratories for research activities. Also, rising pace of development of vaccines for different diseases like liver diseases using albumin is further anticipated to provide opportunities to the companies to develop product portfolio. These factors are likely to drive albumin market in future.

Based on type, the market has been divided into human serum, bovine serum, and recombinant albumin. Among these, the recombinant albumin sub-segment is predicted to be the fastest growing market share in the global market and register an increase in the revenue from $1,011.20 million in 2020 to $2,099.60 million in 2028, at a CAGR of 9.8%.
Based on the application, the market is divided into therapeutics, drugs formulation, and others. The therapeutics sub-segment of market is projected to have the highest share and reach $3,810.60 million by 2028 in a timeframe of 2021-2028.
On the basis of region, the market has been studied for North America, Europe, Asia-Pacific and LAMEA. The Asia-Pacific albumin market is anticipated to grow at a CAGR of 10.3%, by generating a revenue of $2,365.60 million during the review period.

The companies involved in the albumin market are Baxter International Inc., China Biologic Products, Inc, CSL Limited, Grifols, S.A., Merck KGaA, Novozymes, Octapharma AG, Takeda Pharmaceuticals Inc, Thermo Fisher Scientific, and Ventria Bioscience.

❖ レポートの目次 ❖

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters

1.4.1.Assumptions
1.4.2.Forecast parameters

1.5.Data sources

1.5.1.Primary
1.5.2.Secondary

2.Executive Summary

2.1.360° summary
2.2.Types trends
2.3.Application trends

3.Market overview

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of consumers
3.3.2.Bargaining power of suppliers
3.3.3.Threat of new entrants
3.3.4.Threat of substitutes
3.3.5.Competitive rivalry in the market

3.4.Market dynamics

3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities

3.5.Product landscape
3.6.Regulatory landscape
3.7.Patent landscape
3.8.Market value chain analysis
3.9.Strategic overview

4.Albumin Closure Devices Market, by Types

4.1.Human Serum

4.1.1.Key market trends, growth factors, and opportunities
4.1.2.Market size and forecast, by region, 2020-2028
4.1.3.Market share analysis, by country, 2020 & 2028

4.2.Bovine Serum

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region, 2020-2028
4.2.3.Market share analysis, by country, 2020 & 2028

4.3.Recombinant

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region, 2020-2028
4.3.3.Market share analysis, by country, 2020 & 2028

5.Albumin Closure Devices Market, by Application

5.1.Therapeutics

5.1.1.Key market trends, growth factors, and opportunities
5.1.2.Market size and forecast, by region, 2020-2028
5.1.3.Market share analysis, by country, 2020 & 2028

5.2.Drug Formulation

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region, 2020-2028
5.2.3.Market share analysis, by country, 2020 & 2028

5.3.Others

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region, 2020-2028
5.3.3.Market share analysis, by country, 2020 & 2028

6.Albumin Market, by Region

6.1.Overview

6.1.1.Market size and forecast, by region

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by type, 2020-2028
6.2.3.Market size and forecast, by application, 2020-2028
6.2.4.Market size and forecast, by country, 2020-2028

6.2.5.U.S.

6.2.5.1.Market size and forecast, by type, 2020-2028
6.2.5.2.Market size and forecast, by application, 2020-2028

6.2.6.Canada

6.2.6.1.Market size and forecast, by type, 2020-2028
6.2.6.2.Market size and forecast, by application, 2020-2028

6.2.7.Mexico

6.2.7.1.Market size and forecast, by type, 2020-2028
6.2.7.2.Market size and forecast, by application, 2020-2028

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by type, 2020-2028
6.3.3.Market size and forecast, by application, 2020-2028
6.3.4.Market size and forecast, by country, 2020-2028

6.3.5.Germany

6.3.5.1.Market size and forecast, by type, 2020-2028
6.3.5.2.Market size and forecast, by application, 2020-2028

6.3.6.UK

6.3.6.1.Market size and forecast, by type, 2020-2028
6.3.6.2.Market size and forecast, by application, 2020-2028

6.3.7.France

6.3.7.1.Market size and forecast, by type, 2020-2028
6.3.7.2.Market size and forecast, by application, 2020-2028

6.3.8.Spain

6.3.8.1.Market size and forecast, by type, 2020-2028
6.3.8.2.Market size and forecast, by application, 2020-2028

6.3.9.Italy

6.3.9.1.Market size and forecast, by type, 2020-2028
6.3.9.2.Market size and forecast, by application, 2020-2028

6.3.10.Rest of Europe

6.3.10.1.Market size and forecast, by type, 2020-2028
6.3.10.2.Market size and forecast, by application, 2020-2028

6.4.Asia Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by type, 2020-2028
6.4.3.Market size and forecast, by application, 2020-2028
6.4.4.Market size and forecast, by country, 2020-2028

6.4.5.China

6.4.5.1.Market size and forecast, by type, 2020-2028
6.4.5.2.Market size and forecast, by application, 2020-2028

6.4.6.Japan

6.4.6.1.Market size and forecast, by type, 2020-2028
6.4.6.2.Market size and forecast, by application, 2020-2028

6.4.7.India

6.4.7.1.Market size and forecast, by type, 2020-2028
6.4.7.2.Market size and forecast, by application, 2020-2028
6.4.7.3.Market size and forecast, by application, 2020-2028

6.4.8.South Korea

6.4.8.1.Market size and forecast, by type, 2020-2028
6.4.8.2.Market size and forecast, by application, 2020-2028

6.4.9.Australia

6.4.9.1.Market size and forecast, by type, 2020-2028
6.4.9.2.Market size and forecast, by application, 2020-2028

6.4.10.Rest of Asia Pacific

6.4.10.1.Market size and forecast, by type, 2020-2028
6.4.10.2.Market size and forecast, by application, 2020-2028

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by type, 2020-2028
6.5.3.Market size and forecast, by application, 2020-2028
6.5.4.Market size and forecast, by country, 2020-2028

6.5.5.Latin America

6.5.5.1.Market size and forecast, by type, 2020-2028
6.5.5.2.Market size and forecast, by application, 2020-2028

6.5.6.Middle East

6.5.6.1.Market size and forecast, by type, 2020-2028
6.5.6.2.Market size and forecast, by application, 2020-2028

6.5.7.Africa

6.5.7.1.Market size and forecast, by type, 2020-2028
6.5.7.2.Market size and forecast, by application, 2020-2028

7.Company profiles

7.1.Baxter International Inc.

7.1.1.Company overview
7.1.2.Operating business segments
7.1.3.Product portfolio
7.1.4.Financial Performance
7.1.5.Recent strategic moves & developments

7.2.China Biologic Products, Inc

7.2.1.Company overview
7.2.2.Operating business segments
7.2.3.Product portfolio
7.2.4.Financial Performance
7.2.5.Recent strategic moves & developments

7.3.CSL Limited

7.3.1.Company overview
7.3.2.Operating business segments
7.3.3.Product portfolio
7.3.4.Financial Performance
7.3.5.Recent strategic moves & developments

7.4.Grifols, S.A

7.4.1.Company overview
7.4.2.Operating business segments
7.4.3.Product portfolio
7.4.4.Financial Performance
7.4.5.Recent strategic moves & developments

7.5.Merck KGaA

7.5.1.Company overview
7.5.2.Operating business segments
7.5.3.Product portfolio
7.5.4.Financial Performance
7.5.5.Recent strategic moves & developments

7.6.Novozymes

7.6.1.Company overview
7.6.2.Operating business segments
7.6.3.Product portfolio
7.6.4.Financial Performance
7.6.5.Recent strategic moves & developments

7.7.Octapharma AG

7.7.1.Company overview
7.7.2.Operating business segments
7.7.3.Product portfolio
7.7.4.Financial Performance
7.7.5.Recent strategic moves & developments

7.8.Takeda Pharmaceuticals Inc

7.8.1.Company overview
7.8.2.Operating business segments
7.8.3.Product portfolio
7.8.4.Financial Performance
7.8.5.Recent strategic moves & developments

7.9.Thermo Fisher Scientific

7.9.1.Company overview
7.9.2.Operating business segments
7.9.3.Product portfolio
7.9.4.Financial Performance
7.9.5.Recent strategic moves & developments

7.10.Ventria Bioscience

7.10.1.Company overview
7.10.2.Operating business segments
7.10.3.Product portfolio
7.10.4.Financial Performance
7.10.5.Recent strategic moves & developments



★調査レポート[世界のアルブミン市場2021年-2028年:種類別(ヒト血清、ウシ血清、組換え体)、用途別(治療、製剤、その他)、地域別] (コード:RDV22AU024)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のアルブミン市場2021年-2028年:種類別(ヒト血清、ウシ血清、組換え体)、用途別(治療、製剤、その他)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆